Urolithin A During Bedrest in Older Adults
This study will determine whether oral urolithin A (UA) attenuates the loss of knee-extensor strength caused by 10 days of horizontal bed rest in older adults.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
The randomized comparison will also assess muscle mass, cardiorespiratory fitness, physical performance and glucose tolerance, together with cellular mechanisms of muscle adaptation. Orthostatic tolerance, balance responses to galvanic vestibular stimulation (GVS), salivary cortisol, and oral and fecal microbiome profiles will provide complementary exploratory measures of adaptation and recovery.v
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Sharmila Research Coordinator Baccalaureate Nurse
- Número de teléfono: 1+514-984-9975
- Correo electrónico: reachlab@muhc.mcgill.ca
Copia de seguridad de contactos de estudio
- Nombre: Guy Hajj Boutros
- Número de teléfono: 514-501-9975
- Correo electrónico: reachlab@muhc.mcgill.ca
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Men and women at least 65 years of age at enrolment, with a recruitment target of equal numbers of each sex
- English or French speaking
- Females not of childbearing potential
- Willing to maintain current lifestyle and dietary habits, including level of physical activity, allowed medication/supplements habits for the duration of the study
- Physically inactive, defined for eligibility as reporting no more than 2.5 hours of moderate-to-vigorous physical activity per week.
Exclusion Criteria:
- Participated in a clinical trial within 90 days of screening or more than 4 times in the previous year.
- Neuropsychological condition and/or cognitive impairment that, in the QI's opinion, could interfere with study participation.
- Uncontrolled hypothyroidism or hyperthyroidism. Hypothyroid patients who have changed their dose of hormone replacement therapy in the 6 weeks before screening are not eligible.
- Confirmed rheumatoid arthritis, acquired immunodeficiency syndrome (AIDS), type 1 or type 2 diabetes mellitus.
- History of cancer in the last 6 months.
- On any medications including NHPs/living with medical conditions that would compromise the study outcome or the safety of the research participant. For any supplements deemed acceptable, participants must be on a stable dose of allowed supplements/medications for at least 3 months prior to enrollment. All concomitant therapies will be documented.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Bed rest-Urolithin A group (BR-UA)
Participants in BR-UA group will receive a total of 1,000 mg of UA orally each day. |
1000mg Urolithin A daily
Otros nombres:
|
|
Comparador de placebos: BR-PLA group (C)
Participants in group "C" will receive matching placebo. |
Placebo |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in knee extensor strength using biodex at baseline and following the intervention.
Periodo de tiempo: Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)
|
To determine whether UA supplementation reduces the percentage loss of maximal voluntary isometric knee-extensor strength (N) using Biodex between baseline and recovery, compared with placebo. |
Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)
|
|
Changes in V02 using indirect calorimetry at baseline and following the intervention.
Periodo de tiempo: Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)
|
To compare the effects of UA and placebo on cardiorespiratory fitness function using peak oxygen uptake (VO2peak) between baseline and recovery, compared with placebo. |
Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Changes in body composition using DEXA scan at baseline and following the intervention.
Periodo de tiempo: Between baseline testing (B1) and after 10 days of bedrest during the recovery period (R3)
|
To determine whether UA supplementation had an effect on changes in fat free mass and fat mass using the DEXA scan between baseline and recovery, compared with placebo. |
Between baseline testing (B1) and after 10 days of bedrest during the recovery period (R3)
|
|
Changes in mitochondrial respiration at baseline and following the intervention.
Periodo de tiempo: Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R3)
|
To determine whether UA supplementation had an effect on changes in mitochondrial respiration and function using the OROBORUS from muscle biopsy samples between baseline and recovery, compared with placebo. |
Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R3)
|
|
Changes in muscle mass at baseline and following the intervention.
Periodo de tiempo: Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R2)
|
To determine whether UA supplementation had an effect on changes in muscle mass using CT scan between baseline and recovery, compared with placebo. |
Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R2)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Jose A Morais, Medical Doctor, McGill University Health Centre/Research Institute of the McGill University Health Centre
Publicaciones y enlaces útiles
Publicaciones Generales
- Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999 Sep;22(9):1462-70. doi: 10.2337/diacare.22.9.1462.
- Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. JAMA. 2007 Apr 25;297(16):1772-4. doi: 10.1001/jama.297.16.1772-b. No abstract available.
- Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson M, Aebischer P, Auwerx J, Singh A, Rinsch C. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019 Jun;1(6):595-603. doi: 10.1038/s42255-019-0073-4. Epub 2019 Jun 14.
- Utz KS, Korluss K, Schmidt L, Rosenthal A, Oppenlander K, Keller I, Kerkhoff G. Minor adverse effects of galvanic vestibular stimulation in persons with stroke and healthy individuals. Brain Inj. 2011;25(11):1058-69. doi: 10.3109/02699052.2011.607789. Epub 2011 Aug 31.
- Stalder T, Kirschbaum C, Kudielka BM, Adam EK, Pruessner JC, Wust S, Dockray S, Smyth N, Evans P, Hellhammer DH, Miller R, Wetherell MA, Lupien SJ, Clow A. Assessment of the cortisol awakening response: Expert consensus guidelines. Psychoneuroendocrinology. 2016 Jan;63:414-32. doi: 10.1016/j.psyneuen.2015.10.010. Epub 2015 Oct 20.
- Singh A, D'Amico D, Andreux PA, Fouassier AM, Blanco-Bose W, Evans M, Aebischer P, Auwerx J, Rinsch C. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med. 2022 May 17;3(5):100633. doi: 10.1016/j.xcrm.2022.100633.
- Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022 Dec 13;328(22):2252-2264. doi: 10.1001/jama.2022.21022.
- Hopewell S, Chan AW, Collins GS, Hrobjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne D, Farmer A, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson D, Vohra S, White IR, Boutron I. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025 Apr 14;389:e081123. doi: 10.1136/bmj-2024-081123.
- Chan AW, Boutron I, Hopewell S, Moher D, Schulz KF, Collins GS, Tunn R, Aggarwal R, Berkwits M, Berlin JA, Bhandari N, Butcher NJ, Campbell MK, Chidebe RCW, Elbourne DR, Farmer AJ, Fergusson DA, Golub RM, Goodman SN, Hoffmann TC, Ioannidis JPA, Kahan BC, Knowles RL, Lamb SE, Lewis S, Loder E, Offringa M, Ravaud P, Richards DP, Rockhold FW, Schriger DL, Siegfried NL, Staniszewska S, Taylor RS, Thabane L, Torgerson DJ, Vohra S, White IR, Hrobjartsson A. SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ. 2025 Apr 28;389:e081477. doi: 10.1136/bmj-2024-081477.
- Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. TCPS 2. 2022. https://ethics.gc.ca/eng/policy-politique_tcps2-eptc2_2022.html.
- Health Canada. Notice: Period reduced for keeping clinical trial records for drugs and natural health products. 28 March 2022. https://www.canada.ca/en/health-canada/services/clinical-trials/notice-period-reduced-keeping-records-drugs-natural-health-products.html. Accessed 25 September 2026.
- Mirzayi C, Renson A; Genomic Standards Consortium; Massive Analysis and Quality Control Society; Zohra F, Elsafoury S, Geistlinger L, Kasselman LJ, Eckenrode K, van de Wijgert J, Loughman A, Marques FZ, MacIntyre DA, Arumugam M, Azhar R, Beghini F, Bergstrom K, Bhatt A, Bisanz JE, Braun J, Bravo HC, Buck GA, Bushman F, Casero D, Clarke G, Collado MC, Cotter PD, Cryan JF, Demmer RT, Devkota S, Elinav E, Escobar JS, Fettweis J, Finn RD, Fodor AA, Forslund S, Franke A, Furlanello C, Gilbert J, Grice E, Haibe-Kains B, Handley S, Herd P, Holmes S, Jacobs JP, Karstens L, Knight R, Knights D, Koren O, Kwon DS, Langille M, Lindsay B, McGovern D, McHardy AC, McWeeney S, Mueller NT, Nezi L, Olm M, Palm N, Pasolli E, Raes J, Redinbo MR, Ruhlemann M, Balfour Sartor R, Schloss PD, Schriml L, Segal E, Shardell M, Sharpton T, Smirnova E, Sokol H, Sonnenburg JL, Srinivasan S, Thingholm LB, Turnbaugh PJ, Upadhyay V, Walls RL, Wilmes P, Yamada T, Zeller G, Zhang M, Zhao N, Zhao L, Bao W, Culhane A, Devanarayan V, Dopazo J, Fan X, Fischer M, Jones W, Kusko R, Mason CE, Mercer TR, Sansone SA, Scherer A, Shi L, Thakkar S, Tong W, Wolfinger R, Hunter C, Segata N, Huttenhower C, Dowd JB, Jones HE, Waldron L. Reporting guidelines for human microbiome research: the STORMS checklist. Nat Med. 2021 Nov;27(11):1885-1892. doi: 10.1038/s41591-021-01552-x. Epub 2021 Nov 17.
- Gouspillou G, Sgarioto N, Kapchinsky S, Purves-Smith F, Norris B, Pion CH, Barbat-Artigas S, Lemieux F, Taivassalo T, Morais JA, Aubertin-Leheudre M, Hepple RT. Increased sensitivity to mitochondrial permeability transition and myonuclear translocation of endonuclease G in atrophied muscle of physically active older humans. FASEB J. 2014 Apr;28(4):1621-33. doi: 10.1096/fj.13-242750. Epub 2013 Dec 26.
- Holwerda AM, Paulussen KJM, Overkamp M, Smeets JSJ, Gijsen AP, Goessens JPB, Verdijk LB, van Loon LJC. Daily resistance-type exercise stimulates muscle protein synthesis in vivo in young men. J Appl Physiol (1985). 2018 Jan 1;124(1):66-75. doi: 10.1152/japplphysiol.00610.2017. Epub 2017 Sep 21.
- Cefis M, Marcangeli V, Hammad R, Granet J, Leduc-Gaudet JP, Gaudreau P, Trumpff C, Huang Q, Picard M, Aubertin-Leheudre M, Belanger M, Robitaille R, Morais JA, Gouspillou G. Impact of physical activity on physical function, mitochondrial energetics, ROS production, and Ca2+ handling across the adult lifespan in men. Cell Rep Med. 2025 Feb 18;6(2):101968. doi: 10.1016/j.xcrm.2025.101968. Epub 2025 Feb 10.
- Hajj-Boutros G, Sonjak V, Faust A, Balram S, Lagace JC, St-Martin P, Divsalar DN, Sadeghian F, Liu-Ambrose T, Blaber AP, Dionne IJ, Duchesne S, Kontulainen S, Theou O, Morais JA. Myths and Methodologies: Understanding the health impact of head down bedrest for the benefit of older adults and astronauts. Study protocol of the Canadian Bedrest Study. Exp Physiol. 2024 May;109(5):812-827. doi: 10.1113/EP091473. Epub 2024 Feb 19.
- Cipriani E, et al. Mesurer le genre en recherche sur les humains, un nouveau questionnaire adapté. Unité de Soutien SSA Québec. 2022:1-16.
- Marusic U, Narici M, Simunic B, Pisot R, Ritzmann R. Nonuniform loss of muscle strength and atrophy during bed rest: a systematic review. J Appl Physiol (1985). 2021 Jul 1;131(1):194-206. doi: 10.1152/japplphysiol.00363.2020. Epub 2021 Mar 11.
- Liu S, D'Amico D, Shankland E, Bhayana S, Garcia JM, Aebischer P, Rinsch C, Singh A, Marcinek DJ. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Netw Open. 2022 Jan 4;5(1):e2144279. doi: 10.1001/jamanetworkopen.2021.44279.
- Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Moullan N, Nicolet-Dit-Felix AA, Williams EG, Jha P, Lo Sasso G, Huzard D, Aebischer P, Sandi C, Rinsch C, Auwerx J. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med. 2016 Aug;22(8):879-88. doi: 10.1038/nm.4132. Epub 2016 Jul 11.
- Hvid LG, Suetta C, Nielsen JH, Jensen MM, Frandsen U, Ortenblad N, Kjaer M, Aagaard P. Aging impairs the recovery in mechanical muscle function following 4 days of disuse. Exp Gerontol. 2014 Apr;52:1-8. doi: 10.1016/j.exger.2014.01.012. Epub 2014 Jan 18.
- Hajj-Boutros G, Sonjak V, Faust A, Hedge E, Mastrandrea C, Lagace JC, St-Martin P, Naz Divsalar D, Sadeghian F, Chevalier S, Liu-Ambrose T, Blaber AP, Dionne IJ, Duchesne S, Hughson R, Kontulainen S, Theou O, Morais JA. Impact of 14 Days of Bed Rest in Older Adults and an Exercise Countermeasure on Body Composition, Muscle Strength, and Cardiovascular Function: Canadian Space Agency Standard Measures. Gerontology. 2023;69(11):1284-1294. doi: 10.1159/000534063. Epub 2023 Sep 15.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- 2027-13109
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .